Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Significance: Recently developed plant hosts that have been genetically engineered to produce mammalian glycosylation enzymes are capable of producing mAbs with specific glycans that satisfy effector function or homogeneity requirements. When produced in this type of plant system, an antirespiratory syncytial virus mAb containing nearly homogeneous glycans with N-acetylglucosamine termini was found to significantly enhance the effectiveness of the approved antibody drug palivizumab. The improvement was because of augmented effector function via binding to antibody Fc receptors, suggesting that classic viral neutralization plays a secondary role in the in vivo function of this antibody. We conclude that enhanced antibody-dependent cell-mediated cytotoxicity activity can be a potent contributor to the in vivo efficacy of palivizumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nair, H., Nokes, D. J., Gessner, B. D., Dherani, M., Madhi, S. A., Singleton, R. J., O'Brien, K. L., Roca, A., Wright, P. F., Bruce, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60206-1 · Cited by 2,773 · cited 2×
“J Chromatogr B Analyt Technol Biomed Life Sci 848(1):8–18.”
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 1×
“(41) studied the antitumor effects of several therapeutic antibodies, including trastuzumab and rituximab, in the presence of immune effector cells.”
BackgroundShields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835 · cited 1×
“(42) found that fucose-depleted trastuzumab results in (i) improved binding to the activating Fc receptors on NK cells and (ii) a 43-fold increase in the potency of ADCC against breast cancer cells in vitro.”
BackgroundShinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413 · cited 1×
“(43) found that the removal of fucose produces a significant enhancement of cytotoxic potency against the Raji CD20-overexpressing human B lymphoma cell line.”
Background
Cited by
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
Lee, W. S., Wheatley, A. K., Kent, S. J., & DeKosky, B. J. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00789-5 · Cited by 676
The role of IgG Fc receptors in antibody-dependent enhancement
Bournazos, S., Gupta, A., & Ravetch, J. V. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00410-0 · Cited by 617
Liu, L. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24444 · Cited by 428
A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants
Zhu, Q., McLellan, J. S., Kallewaard, N. L., Ulbrandt, N. D., Palaszynski, S., Zhang, J., Moldt, B., Khan, A., Svabek, C., McAuliffe, J. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaj1928 · Cited by 362
Pereira, N. A., Chan, K. F., Lin, P. C., & Song, Z. (2018) · mAbs · doi:10.1080/19420862.2018.1466767 · Cited by 334
Metadata
- Authors
- Hiatt, A., Bohorova, N., Bohorov, O., Goodman, C., Kim, D., Pauly, M. H., Velasco, J., Whaley, K. J., Piedra, P. A., Gilbert, B. E., & Zeitlin, L.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2014-04-07
- Volume
- 111
- Issue
- 16
- Pages
- 5992-5997
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2001683849
- Cited by
- 119
- References
- 4
- FWCI
- 8.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. https://app.cochat.ai/papers/10.1073/pnas.1402458111
- The paper
- Hiatt, A., Bohorova, N., Bohorov, O., Goodman, C., Kim, D., Pauly, M. H., Velasco, J., Whaley, K. J., Piedra, P. A., Gilbert, B. E., & Zeitlin, L. (2014). Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1402458111
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.